simoa hd 1 analyzer (Quanterix)
Structured Review
Simoa Hd 1 Analyzer, supplied by Quanterix, used in various techniques. Bioz Stars score: 99/100, based on 3159 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hd+1+immunoassay+analyzer/HD-X+Automated+Immunoassay+Analyzer/pmc13694781-107-12-15
Average 99 stars, based on 3159 article reviews
Images
Related Articles
Concentration Assay:Article Title: Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Article Snippet: .. The concentration of NfL protein was determined in duplicates by investigators blinded to the clinical data using an Article Title: Skin innervation across amyotrophic lateral sclerosis clinical stages: new prognostic biomarkers. Article Snippet: 7 In the last decades, peripheral sensory abnormalities, including the evidence of cutaneous 8 denervation, have been reported among the non-motor manifestations in amyotrophic lateral 9 sclerosis (ALS).. However, a correlation between cutaneous innervation and clinical features has 10 not been found.. 11 Aims of this study were to assess sensory involvement by applying a morpho-functional 12 approach on a large population of ALS patients stratified according to King’s stages and to 13 correlate these findings with the severity and prognosis of the disease. other:Article Title: Eculizumab for the acute attack of neuromyelitis optica spectrum disorder Article Snippet: Neurology 2-plex B kits were used with an Article Title: Eculizumab for the acute attack of neuromyelitis optica spectrum disorder Article Snippet: Neurology 2-plex B kits were used with an Clinical Proteomics:Article Title: CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review Article Snippet: Axelson et al., 2018 , 18 GBS patients , Outcome , NfL , ELISA , Poor outcome in patients with NfL levels over 10,000 ng/L. .. Mariotto et al., 2018 , GBS (N = 5), MMN (N = 3), CIDP and variants (N = 12), anti-MAGneuropathy (N = 3), and non-systemic vasculitic neuropathy (N = 1) , Outcome , NfL , |

